Avid Bioservices Inc (CDMO)

[biopharm]

Hakan Mellstedt : Peregrine Pharmaceuticals KOL :

Professor Håkan Mellstedt, who researched for many years if immunotherapy, told the recent years made ??a major breakthrough in this field, we also talk about the recent Cancer Fund report . He described immunotherapy as a fourth piece in the treatment of cancer patients, along with the three traditional: surgery, radiation and chemotherapy.

- There are promising results for a variety of cancers, and I believe that some form of immunotherapy will be included in the treatment of 60 percent of all cancer patients in ten years, predicted Hakan Mellstedt.

Now, that quote above from the previous post was made by Peregsrine KOL Hakan Mellstedt back on July 1, 2014. Since Hakan Mellstedt has joined the scientific advisors of only Peregrine Pharmaceuticals within the past 8 months and believes immuno-therapy will be included in the treatment of 60% of all cancer patients...... can one conclude that Peregrine Pharmaceuticals has convinced him of this new way of thinking ? I say yes

Remember, Hakan Mellstedt was one of the 4 additions of scientifica advisors back on Dec 10, 2013 and how does Peregrine bring on board not only 1.... but four (4)!, global leaders in their respective fields of immunotherapy .... all in the same time frame of Dec 2013 ? I'd say the MOA of Bavituximab had all to do with that accomplishment.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=94846768&txt2find=scientific|advisors